BG106695A - 2,4-диаминопиримидинови съединения, полезни като антисупресанти - Google Patents

2,4-диаминопиримидинови съединения, полезни като антисупресанти Download PDF

Info

Publication number
BG106695A
BG106695A BG106695A BG10669502A BG106695A BG 106695 A BG106695 A BG 106695A BG 106695 A BG106695 A BG 106695A BG 10669502 A BG10669502 A BG 10669502A BG 106695 A BG106695 A BG 106695A
Authority
BG
Bulgaria
Prior art keywords
alkyl
aryl
heteroaryl
dihydro
amino
Prior art date
Application number
BG106695A
Other languages
Bulgarian (bg)
English (en)
Inventor
Todd Blumenkopf
Eileen Mueller
Eric ROSKAMP
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG106695A publication Critical patent/BG106695A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BG106695A 1999-11-30 2002-05-13 2,4-диаминопиримидинови съединения, полезни като антисупресанти BG106695A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16822499P 1999-11-30 1999-11-30
PCT/IB2000/001628 WO2001040215A1 (en) 1999-11-30 2000-11-09 2,4-diaminopyrimidine compounds usful as immunosuppressants

Publications (1)

Publication Number Publication Date
BG106695A true BG106695A (bg) 2002-12-29

Family

ID=22610621

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106695A BG106695A (bg) 1999-11-30 2002-05-13 2,4-диаминопиримидинови съединения, полезни като антисупресанти

Country Status (33)

Country Link
EP (1) EP1242403B1 (de)
JP (1) JP3955468B2 (de)
KR (1) KR20020059826A (de)
CN (1) CN1402720A (de)
AP (1) AP2002002530A0 (de)
AT (1) ATE315036T1 (de)
AU (1) AU1047601A (de)
BG (1) BG106695A (de)
BR (1) BR0015995A (de)
CA (1) CA2392971C (de)
CO (1) CO5261519A1 (de)
CZ (1) CZ20021703A3 (de)
DE (1) DE60025385T2 (de)
EA (1) EA200200411A1 (de)
EE (1) EE200200275A (de)
ES (1) ES2253266T3 (de)
GT (1) GT200000200A (de)
HN (1) HN2000000264A (de)
HU (1) HUP0203300A3 (de)
IL (1) IL149103A0 (de)
IS (1) IS6339A (de)
MA (1) MA26846A1 (de)
MX (1) MXPA02005350A (de)
NO (1) NO20022557D0 (de)
OA (1) OA12097A (de)
PA (1) PA8506801A1 (de)
PE (1) PE20010900A1 (de)
PL (1) PL355946A1 (de)
SV (1) SV2002000231A (de)
TN (1) TNSN00232A1 (de)
TR (1) TR200201431T2 (de)
UY (1) UY26455A1 (de)
WO (1) WO2001040215A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301117A3 (en) * 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
BR0113574A (pt) * 2000-08-31 2003-07-22 Pfizer Prod Inc Derivados de pirazol e uso dos mesmos como inibidores de proteìna quinase
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
KR100909665B1 (ko) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
NZ538426A (en) 2002-08-02 2007-05-31 Vertex Pharma Pyrazole compositions useful as inhibitors of glycogen synthase kinase-3 (GSK-3)
US20040204458A1 (en) 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
DE10237423A1 (de) * 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
CN1910159A (zh) * 2004-01-16 2007-02-07 诺瓦提斯公司 2,4－二氨基嘧啶和它们用于诱导心肌发生的用途
MX2007004526A (es) * 2004-10-12 2007-09-21 Decode Genetics Inc Arilsulfonamidas biciclicas peri-sustituidas para la enfermedad arterial oclusiva.
US20060161001A1 (en) * 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
DE602007008837D1 (de) 2006-02-14 2010-10-14 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
CA2644356A1 (en) * 2006-03-16 2007-09-27 Novartis Ag Heterocyclic organic compounds for the treatment of in particular melanoma
WO2008141081A1 (en) 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
AU2008312948C1 (en) * 2007-10-16 2012-08-09 Daiichi Sankyo Company, Limited Pyrimidyl indoline compound
CA2773742C (en) 2009-09-25 2017-12-05 Vertex Pharmaceuticals Incorporated Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
CN103492391A (zh) 2009-09-25 2014-01-01 沃泰克斯药物股份有限公司 用于制备用作蛋白激酶抑制剂的嘧啶衍生物的方法
TWI513694B (zh) * 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
KR101708761B1 (ko) * 2012-04-13 2017-02-21 주식회사 머쉬메드 퓨린 유도체 또는 그의 염을 포함하는 아토피성 피부염의 예방 또는 치료용 조성물
EP3055301B1 (de) * 2013-10-07 2019-11-20 Kadmon Corporation, LLC (2-(5-isoindolin-2-yl)pyrimidin-4-yl)-amin-derivate als rho kinase inhibitoren zur behandlung von autoimmun-erkrankungen
ES2969536T3 (es) * 2017-06-30 2024-05-21 Beijing Tide Pharmaceutical Co Ltd Inhibidor de la proteína cinasa asociada a rho, composición farmacéutica que lo comprende, y su método de preparación y uso
CN110582491B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
ES2930804T3 (es) * 2017-06-30 2022-12-22 Beijing Tide Pharmaceutical Co Ltd Inhibidor de proteína cinasa asociada a RHO, composición farmacéutica que lo comprende, así como método de preparación y uso del mismo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0837063A1 (de) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
HUP0203300A2 (hu) 2003-02-28
WO2001040215A1 (en) 2001-06-07
PA8506801A1 (es) 2002-04-25
MXPA02005350A (es) 2002-12-11
GT200000200A (es) 2002-05-23
DE60025385T2 (de) 2006-08-24
HUP0203300A3 (en) 2003-10-28
EE200200275A (et) 2003-10-15
EP1242403B1 (de) 2006-01-04
OA12097A (en) 2006-05-04
CA2392971A1 (en) 2001-06-07
UY26455A1 (es) 2001-07-31
ES2253266T3 (es) 2006-06-01
MA26846A1 (fr) 2004-12-20
DE60025385D1 (de) 2006-03-30
PL355946A1 (en) 2004-05-31
CA2392971C (en) 2008-10-07
JP3955468B2 (ja) 2007-08-08
IS6339A (is) 2002-04-12
NO20022557L (no) 2002-05-29
KR20020059826A (ko) 2002-07-13
AU1047601A (en) 2001-06-12
BR0015995A (pt) 2002-08-06
CZ20021703A3 (cs) 2003-06-18
EP1242403A1 (de) 2002-09-25
EA200200411A1 (ru) 2002-10-31
AP2002002530A0 (en) 2002-06-30
IL149103A0 (en) 2002-11-10
CO5261519A1 (es) 2003-03-31
TR200201431T2 (tr) 2002-09-23
HN2000000264A (es) 2001-05-21
ATE315036T1 (de) 2006-02-15
CN1402720A (zh) 2003-03-12
PE20010900A1 (es) 2001-09-08
TNSN00232A1 (fr) 2005-11-10
SV2002000231A (es) 2002-07-16
NO20022557D0 (no) 2002-05-29
JP2003515602A (ja) 2003-05-07

Similar Documents

Publication Publication Date Title
BG106695A (bg) 2,4-диаминопиримидинови съединения, полезни като антисупресанти
US7101869B2 (en) 2,4-diaminopyrimidine compounds useful as immunosuppressants
JP6704398B2 (ja) ４Ｈ−ピロロ［３，２−ｃ］ピリジン−４−オン誘導体
CN106467541B (zh) 取代喹诺酮类衍生物或其药学上可接受的盐或立体异构体及其药用组合物和应用
CA3177200A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
TWI361187B (en) Organic compounds
TWI534145B (zh) 四氫吡啶并嘧啶衍生物
JP5830094B2 (ja) 置換イミダゾ［１，２−ａ］ピリミジンおよび−ピリジン
CA3173955A1 (en) Methods of using myt1 inhibitors
CA3039760A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
CN103998042B (zh) Pi3k的活性或功能的抑制剂的应用
JP5507546B2 (ja) 置換イミダゾ−およびトリアゾロピリミジン類、イミダゾ−およびピラゾロピラジン類およびイミダゾトリアジン類
JP2005500294A (ja) ホスホジエステラーゼ７に対するピリミジン阻害剤
EA024109B1 (ru) Ингибиторы протеинкиназ
TW201605794A (zh) 吡咯啶－２，５－二酮衍生物、醫藥組合物及用做為ｉｄｏ１抑制劑之方法
TW201313725A (zh) ６Ｈ－噻吩并［３，２－ｆ］［１，２，４］三唑并［４，３－ａ］［１，４］二氮呯
JP5667085B2 (ja) Ａｋｔインヒビターとしての融合されたピリミジン
KR20150093687A (ko) Ａｌｋ 키나아제 억제제
HUE029326T2 (hu) Szubsztituált alifánok, ciklofánok, heterafánok, heterofánok, hetero-heterafánok és metallocének, amelyek alkalmasak HCV fertõzések kezelésére
JP2013532675A (ja) 置換イミダゾ［１，２−ｂ］ピリダジン
JP2010521506A (ja) 置換イミダゾおよびトリアゾロピリミジン類
CN101137382A (zh) 含有杂环化合物作为活性成分的免疫抑制剂和抗肿瘤剂
CN102015717A (zh) 趋化因子受体调节剂
TW200804364A (en) New compounds
TW201120042A (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes